tramadol + celecoxib

**Tramadol + celecoxib** is an oral fixed-dose analgesic combination of tramadol, an atypical opioid analgesic that also inhibits serotonin and norepinephrine reuptake, and celecoxib, a selective cyclooxygenase-2 inhibitor. The marketed US co-crystal product is **Seglentis**, developed by Esteve as E-58425 and approved for management of acute pain in adults severe enough to require an opioid analgesic when alternative treatments are inadequate. The term is non-specific because it can also refer to distinct investigational fixed-dose formulations, including Yooyoung Pharmaceutical's YYC301 program for knee osteoarthritis. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213426s003lbl.pdf))

Brand names

SeglentisVELYNTRA

Other names

celecoxib + tramadolcelecoxib/tramadoltramadol + celecoxibtramadol-celecoxibtramadol/celecoxib